FDA granted Orphan Drug Designation to Sanofi’s SAR446523, a monoclonal antibody targeting GPRC5D, for relapsed/refractory ...

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for ...

Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted ...

Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment ...

G protein-coupled receptor, class C, group 5, member D (GPRC5D) loss after chimeric antigen receptor (CAR) T-cell therapy in ...

DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices ...

Targeting the GPRC5D protein expressed in myeloma, the CAR T-cell therapy led to objective responses in 31 of 37 patients. More than a third of the patients had complete response or better.

A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple ...

The Future of BCMA- and GPRC5D-Targeted Immunotherapy for Multiple Myeloma GPRC5D continues to offer promise for patients with multiple myeloma. In September 2022, Dr. Mailankody reported encouraging ...

GPRC5D-directed Therapies Epidemiology Segmentation The GPRC5D-directed therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: ...

US FDA grants orphan drug designation to Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns to treat multiple myeloma: Paris Friday, August 1, 2025, 09:00 Hrs [IST] The US ...